Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $122,374.85 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Los Pinos Elisabet De sold 15,955 shares of Aura Biosciences stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the sale, the insider now directly owns 304,692 shares of the company’s stock, valued at $2,336,987.64. The trade was a 4.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Los Pinos Elisabet De also recently made the following trade(s):

• On Tuesday, October 29th, Los Pinos Elisabet De sold 9,200 shares of Aura Biosciences stock. The stock was sold at an average price of $10.74, for a total transaction of $98,808.00.

Aura Biosciences Stock Performance

NASDAQ:AURA opened at $8.10 on Friday. The firm’s fifty day moving average is $8.45 and its 200-day moving average is $8.91. Aura Biosciences, Inc. has a 52 week low of $6.63 and a 52 week high of $12.38. The firm has a market cap of $404.60 million, a P/E ratio of -4.68 and a beta of 0.30.

Aura Biosciences (NASDAQ:AURA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.02. As a group, sell-side analysts anticipate that Aura Biosciences, Inc. will post -1.67 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on AURA shares. Scotiabank boosted their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a report on Friday, October 18th. BTIG Research boosted their price objective on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a report on Friday, October 18th. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Aura Biosciences in a report on Thursday, November 14th. Finally, Cowen reissued a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Aura Biosciences presently has an average rating of “Buy” and an average target price of $23.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. raised its holdings in shares of Aura Biosciences by 2.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock valued at $1,233,000 after purchasing an additional 3,612 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Aura Biosciences by 14.6% in the second quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock valued at $487,000 after purchasing an additional 8,194 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Aura Biosciences by 26.3% in the second quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock valued at $545,000 after purchasing an additional 15,000 shares during the last quarter. American Century Companies Inc. purchased a new stake in shares of Aura Biosciences in the second quarter valued at about $119,000. Finally, Rhumbline Advisers raised its holdings in shares of Aura Biosciences by 39.6% in the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after purchasing an additional 18,011 shares during the last quarter. 96.75% of the stock is owned by institutional investors.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.